Some researchers have used MSCs genetically modified with factors such as CXCR4, basic fibrosis growth factor (bFGF), and HGF to mitigate the effects of acute and chronic lung injuries and pulmonary fibrosis [35–37]. Here, FGF2 is linked to injury.